Houston-based Decisio's virtual care technology has been paired with GE Healthcare and Microsoft technology in a new initiative for hospitals dealing with the COVID-19 outbreak. Photo via decisiohealth.com

Houston-based health tech startup Decisio Health Inc. has been enlisted in the war against the novel coronavirus.

Chicago-based GE Healthcare Inc. has tapped Decisio's AI-powered DECISIOInsight software, which enables health care providers to remotely monitor patients, for an initiative involving Redmond, Washington-based Microsoft Corp. that's designed to help treat COVID-19 patients.

The coronavirus-targeted Mural Virtual Care Solution, which was introduced April 15, marries Decisio's virtual monitoring software with GE Healthcare's telehealth technology and Microsoft's Azure cloud-computing platform. It's designed to offer hospitals a broad view of COVID-19 patients who are hooked up to ventilators in ICUs. This platform merges data from ventilators, patient monitoring systems, electronic health records, labs, and other sources.

This special technology package is a stripped-down version of the Mural Virtual Care Solution, which pairs Decisio's and GE Healthcare's technology to virtually track hospital patients. GE Healthcare invested in Decisio in 2019.

Until January 31, 2021, the Mural coronavirus bundle is being provided at no cost to hospitals. Among the users is Oregon Health & Science University in Portland.

"We're trying to carry as much of the cost burden to make this as sustainable as possible for our hospital partners that we know are hurting economically right now," says Bryan Haardt, CEO of Decisio.

"There has to be a moralistic compass," he adds. "You have to be driven by something more than just profit."

GE Healthcare, which contributed to Decisio's $13 million Series B round in December, was already partnering with the startup on the Mural Virtual Care Solution. Microsoft was brought into the mix to speed up delivery of the platform in response to the coronavirus pandemic.

"This relationship did not exist prior to this initiative," Haardt says. "We all came together and said, 'Guys, we've got to do our part. It is absolutely a moral imperative that we get together.' And we said, 'OK, well, what are the parts?'"

Haardt says this project equips hospitals to adhere to the best standards of care when it comes to treating COVID-19 patients who are relying on ventilators. In a COVID-19 treatment setting, one of the key benefits of the Mural Virtual Care Solution is that a health care clinician can monitor a patient's vital signs and other data without physical contact, he says.

Founded in 2013, Decisio built its virtual health platform using technology licensed from and developed at the University of Texas Health Science Center in Houston. Coupling real-time clinical surveillance with data visualization, the DECISIOInsight software can pinpoint risks and guide clinicians toward better decisions about patient care.

Haardt says Decisio's software aims to reduce the rate of hospital deaths, length of hospital stays, and burden on hospital resources by helping health care providers decrease the severity of hospital-acquired infections, pneumonia, the flu, and other conditions. Baylor St. Luke's Medical Center in Houston is among the customers for Decisio and GE Healthcare's broad-based Mural Virtual Care Solution, which was rolled out last year.

Also, Decisio has teamed up with professional services firm Deloitte to deliver virtual patient monitoring at U.S. Department of Defense hospitals. This technology is being piloted at Brooke Army Medical Center in San Antonio and Naval Medical Center San Diego.

"We look at doctors and nurses as heroes, because they're really good at getting people out of trouble," Haardt says. "And we like to think of our solution as keeping people out of trouble, because if you can keep them out of the trouble, then these heroic, herculean efforts [by doctors and nurses] are not required as much … ."

Haardt explains that Decisio's technology can monitor patient activity and detect patient trends in not just one area of a hospital (such as an ICU) or throughout an entire hospital but across a commonly managed group of hospitals. Those insights help hospitals ensure all of their health care professionals are following the same treatment protocols.

The No. 1 economic detriment to hospitals "is doing things different at all their different facilities," Haardt says. "If you can reduce the variability of care, we know the cost to provide goods and services goes down, and we know the outcomes improve."

Decisio Health Inc. is designing data-driven resources for clinicians and patients using virtual care. Photo via decisiohealth.com

Houston virtual health care company receives investment from GE for its $13M series B

Money moves

A Houston-based health tech company is wrapping up its series B fundraising round with an investment from Chicago-based GE Healthcare.

The fundraising round is in its initial closing, says Gray Hancock, COO Decisio Health Inc., and is expected to close at $13 million. Decisio has previously raised $7 million, according to Crunchbase. The funds will be used for product development, support, and ongoing growth in operations.

"This investment really cements our partnership with GE Healthcare," Hancock tells InnovationMap in an email. "We signed a global distribution agreement with them earlier this year, so the investment is another step forward in our strategic alignment."

GE Healthcare also invested in Massachusetts-based Formlabs, which makes low-cost 3D printers for anatomical models, and U.K.-based CMR Surgical Ltd., which specializes in surgical robotics.

"Healthcare's next chapter will be written in part by emerging technologies like 3D printing, robotic surgery and virtual patient monitoring," says Kieran Murphy, president and CEO of GE Healthcare, in a news release. "That's why we're putting GE Healthcare's innovative engine and resources behind collaborations with these exciting, next generation companies – to help change the way clinicians work and enable more precise patient care."

Decisio is a virtual care monitoring software that was founded in 2013 based on technology licensed from and developed at the University of Texas Health Science Center in Houston. Using real-time clinical surveillance with data visualization, the DECISIOInsight software can identify risk that helps clinicians make better patient care decisions virtually.

"Our theory was that if you can make the clinicians job's easier, and improve the outcomes for the patients then costs will come down," Hancock says. "But the care of the patient comes first. Do that right and the cost savings will follow. We say its 'where outcomes meet income.'"

In 2015, Decisio Health was approved by the Food and Drug Administration class II medical device, which made it the first FDA-cleared web-native software.

For Decisio, the future of health care is virtual, and the company is determined to design the best technology for clinicians and patients alike.

"Virtual Care is the next step beyond traditional telemedicine, which — for many years — was limited to having a teleconference or even just a phone call with a caregiver," Hancock says. "Now we can start sharing real-time clinical data with clinicians wherever they happen to be located."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”